MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith acquired 25,000 shares of the company's stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $1.87 per share, for a total transaction of $46,750.00. Following the completion of the purchase, the director now directly owns 1,130,060 shares of the company's stock, valued at approximately $2,113,212.20. This represents a 2.26 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
MAIA Biotechnology Trading Down 0.5 %
MAIA opened at $2.00 on Friday. MAIA Biotechnology, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $5.99. The stock has a market capitalization of $50.66 million, a P/E ratio of -1.45 and a beta of 0.14.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.21. Equities analysts forecast that MAIA Biotechnology, Inc. will post -1.3 EPS for the current fiscal year.
Institutional Investors Weigh In On MAIA Biotechnology
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ground Swell Capital LLC purchased a new stake in MAIA Biotechnology in the 2nd quarter valued at about $56,000. Geode Capital Management LLC boosted its stake in shares of MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company's stock worth $541,000 after buying an additional 35,821 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of MAIA Biotechnology in the third quarter valued at approximately $31,000. 5.65% of the stock is owned by hedge funds and other institutional investors.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
